Linden Capital Partners
Needle-free drug delivery company Bioject Medical Technologies (OTC:BJCT) announced the departure of its president & CEO "for cost-cutting reasons" on the heels of major cuts to its workforce.
Ralph Makar, who took the corner office at Bioject four years ago, ceded his role to board member Mark Logomasini, who will serve as interim president & CEO, effective immediately.
The souring economy put a dent in the white-hot leveraged buyout market for the med-tech industry, a panel of fund managers said yesterday at the AdvaMed 2011 conference in Washington.
The European banks crisis, an uncertain regulatory environment in the U.S. and a looming new tax on medical devices all have mixed into a toxic stew that’s choking the LBO market, which had surged back since the economic slump in 2009.